Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
JAGX 
Jaguar Animal Health Inc (JAGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: JAGX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $25.5
1 Year Target Price $25.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -88.61% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.51M USD | Price to earnings Ratio - | 1Y Target Price 25.5 |
Price to earnings Ratio - | 1Y Target Price 25.5 | ||
Volume (30-day avg) 2 | Beta -0.4 | 52 Weeks Range 0.92 - 26.00 | Updated Date 01/9/2026 |
52 Weeks Range 0.92 - 26.00 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -234.77% |
Management Effectiveness
Return on Assets (TTM) -38.01% | Return on Equity (TTM) -411.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 35367903 | Price to Sales(TTM) 0.38 |
Enterprise Value 35367903 | Price to Sales(TTM) 0.38 | ||
Enterprise Value to Revenue 3 | Enterprise Value to EBITDA -0.63 | Shares Outstanding 4175837 | Shares Floating 2114334 |
Shares Outstanding 4175837 | Shares Floating 2114334 | ||
Percent Insiders 43.85 | Percent Institutions 2.1 |
Upturn AI SWOT
Jaguar Animal Health Inc
Company Overview
History and Background
Jaguar Animal Health Inc. was a late-stage veterinary pharmaceutical company focused on developing and commercializing novel therapeutics for companion animals and livestock. The company was founded in 2013. A significant milestone was its IPO in 2015. In 2019, the company underwent a corporate rebranding and merger, becoming Catalyst Biosciences, Inc., which later evolved further. Therefore, 'Jaguar Animal Health Inc.' as a distinct publicly traded entity no longer exists.
Core Business Areas
- Animal Health Therapeutics: Jaguar Animal Health focused on developing prescription drugs for unmet medical needs in animals. Their pipeline included products targeting gastrointestinal disorders and other prevalent conditions in pets and livestock.
Leadership and Structure
As Jaguar Animal Health Inc., the company had a management team and board of directors typical of a publicly traded biopharmaceutical company. However, with its subsequent merger and rebranding, the original leadership structure is no longer relevant to the current entity.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
The animal health industry is characterized by a growing demand for innovative veterinary pharmaceuticals driven by increased pet ownership, humanization of pets, and the need for efficient livestock production. The market is competitive with established players and emerging biotechs.
Positioning
Jaguar Animal Health aimed to position itself as a developer of specialty pharmaceuticals for niche markets within the broader animal health sector. Its competitive advantage was intended to stem from its novel product pipeline and scientific expertise. However, its market penetration was limited due to its stage of development and subsequent corporate changes.
Total Addressable Market (TAM)
The global animal health market is substantial and growing, with estimates ranging in the tens of billions of dollars annually. Jaguar Animal Health Inc. targeted specific segments within this TAM. Its positioning relative to the overall TAM was that of a niche player with potential for significant impact within its focused areas.
Upturn SWOT Analysis
Strengths
- Focus on novel therapeutics for unmet medical needs
- Late-stage development pipeline at its peak
- Experienced management team in animal health (at the time)
Weaknesses
- Limited commercialization experience
- Reliance on successful drug development and regulatory approval
- Capital intensive nature of drug development
- Subsequent corporate restructuring indicates financial or strategic challenges
Opportunities
- Increasing pet humanization and spending on pet care
- Growing demand for advanced veterinary treatments
- Potential for partnerships and collaborations with larger animal health companies
Threats
- Intense competition from established pharmaceutical giants
- Regulatory hurdles and lengthy approval processes
- Failure to achieve clinical endpoints or market acceptance
- Evolving market dynamics and competitor innovations
Competitors and Market Share
Key Competitors
Competitive Landscape
The competitive landscape for Jaguar Animal Health Inc. was populated by both large, diversified animal health companies and smaller biotechnology firms. Its key advantage was intended to be its specialized focus and innovative therapies, but it faced challenges in competing for market share and resources against well-established entities.
Growth Trajectory and Initiatives
Historical Growth: The historical growth trajectory of Jaguar Animal Health Inc. was focused on advancing its product pipeline through clinical trials and seeking regulatory approvals. Growth was measured by pipeline progression rather than traditional revenue growth.
Future Projections: Future projections for Jaguar Animal Health Inc. are moot as the company no longer exists in its original form. Any projections would have been based on the expected success of its drug candidates and market penetration.
Recent Initiatives: The most significant 'recent initiative' for Jaguar Animal Health Inc. was its merger/rebranding, which fundamentally altered its corporate identity and operations.
Summary
Jaguar Animal Health Inc. was a veterinary pharmaceutical company focused on novel therapeutics. It faced typical challenges of drug development, including regulatory hurdles and capital intensity. The company's trajectory was significantly altered by subsequent mergers and rebranding, meaning its original business and market position are no longer applicable. It no longer operates as an independent entity, making a current assessment of its strength impossible.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company historical SEC filings (e.g., 10-K, 10-Q)
- Financial news archives
- Industry analysis reports (general knowledge of animal health market)
Disclaimers:
This analysis pertains to Jaguar Animal Health Inc. as it existed prior to its subsequent corporate actions. The company no longer operates under this name or structure. Information is based on historical data and general industry knowledge. No guarantee is made as to the accuracy or completeness of this information, and it should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jaguar Animal Health Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2015-05-13 | Founder, CEO, President & Director Ms. Lisa A. Conte | ||
Sector Healthcare | Industry Biotechnology | Full time employees 49 | Website https://jaguar.health |
Full time employees 49 | Website https://jaguar.health | ||
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.